Coke biopharmaceutical industry, Xi'an City issued a number of policies to support industrial development.

Pharmaceutical Network Policy and Regulation: Biopharmaceutical industry is one of China's strategic emerging industries.
According to the definition of the industry, refers to the genetic engineering, cell engineering, enzyme engineering, fermentation engineering and protein engineering and other biotechnology research results applied to the pharmaceutical industry, manufacturing marketable drugs and large-scale production of economic entities.
, the pace of development of biopharmaceutical industry has accelerated, with it as the focus of development, and policies have been put in place to support it.
For example, Guangzhou issued "Guangzhou City to accelerate the development of biopharmaceutical industry", Shenzhen issued "Shenzhen City to promote the development of biopharmaceutical industry gathering guidance" and "Shenzhen biopharmaceutical industry cluster development implementation plan (2020-2025)" "Shenzhen Biopharmaceutical Industry Development Action Plan (2020-2025)" and so on.
coke biopharmaceutical industry, Xi'an City in recent years has also introduced a number of policies to support the development of biopharmaceutical industry.
At the end of 2019, Xi'an City issued an implementation opinion clearly, to the biopharmaceutical industry as one of the six pillar industries, based on chemical drugs, traditional Chinese medicine, biological medicine, medical devices industry, 3D printing, optical equipment, regenerative medicine, gene sequencing, peptides and proteins and other high-precision technology as the lead, around "strong modern Chinese medicine, To optimize the study of medicine, large biological medicine, do refined medical equipment, do special health tourism "five key areas, the implementation of "industry foundation cultivation, industrial innovation transformation, industrial cooperation promotion, industrial digital transformation" four major projects, to promote the stock upgrade transformation and incremental cultivation breakthrough, to build a national biopharmaceutical industry (high-end medical devices) innovation base and serve the "Belt and Road" health tourism destination.
In addition, Xi'an City has also issued a series of biopharmaceutical industry support policies, such as the Xi'an Biopharmaceutical Industry Cluster Development Action Plan (2020-2022), and set up a 100 billion yuan Xi'an Science and Technology Industry Development Fund, the xi'an High-tech Zone "New Silk Road" talent innovation and entrepreneurship measures, on promoting the development of the biotechnology industry in Xi'an City, a number of policy recommendations to attract more biopharmaceutical industry-related enterprises and talent settled in Xi'an.
At present, There are 2,758 biopharmaceutical production and research and development enterprises in Xi'an, which have formed a biopharmaceutical industry development pattern based on chemical medicine, traditional Chinese medicine, biological medicine and medical device industry, with Xi'an New Area, High-tech Zone and The Open Zone as the main carriers.
, Xi'an High-tech District is the core area of the city's biopharmaceutical industry development, which currently has 73 pharmaceutical manufacturing enterprises, 45 circulation industry enterprises, 33 production and service industry enterprises, a total of 24 enterprises sales of more than 100 million yuan.
2019, the district also released a plan of action to create four innovative industrial clusters of 100 billion yuan by 2025, including the electronic information industry, the automotive industry, the high-end equipment industry, and the biopharmaceutical industry.
In recent years, Xi'an biopharmaceutical industry has shown a large-scale development trend, forming a number of domestic well-known enterprises as the representative of the chemical and preparation production cluster, traditional Chinese medicine production cluster, natural plant extraction production cluster, gene testing cluster, medical device production and sales cluster, and attracted such as Johnson and Johnson, Yang Sen as the representative of the world's top 500 biopharmaceutical enterprises settled in Xi'an.
that by 2020, the total output value of the biopharmaceutical industry in Xi'an is expected to reach 50 billion yuan.
.